MPP+ iodide

Catalog No.S6301 Batch:S630103

Print

Technical Data

Formula

C12H12IN
Molecular Weight 297.13 CAS No. 36913-39-0
Solubility (25°C)* In vitro DMSO 59 mg/mL (198.56 mM)
Ethanol 14 mg/mL (47.11 mM)
Water Insoluble
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description MPP+ iodide (N-Methyl-4-Phenylpyridinium Iodide), the metabolite of a neurotoxin MPTP, causes symptom of Parkinson's disease (PD) in animal models by selectively destroying dopaminergic neurons in substantia nigra. MPP+ induces autophagic cell death in SH-SY5Y cells. MPP+ induces dopamine transporter (DAT) externalization in dopaminergic (DA) neurons, but internalization of serotonin transporter (SERT) in serotonergic (5-HT) neurons.
Targets
DAT [1] SERT [1]
In vitro

Vacuolin-1 potently and reversibly inhibits the fusion between autophagosomes and lysosomes in mammalian cells, thereby inducing the accumulation of autophagosomes. Vacuolin-1 activates RAB5A to block autophagosome-lysosome fusion. [1]
In vivo

MPP+ iodide decreases mitochondrial oxidation-reduction activity and membrane potential in rat striatum.

Protocol (from reference)

Cell Assay:

[1]
  • Cell lines

    HeLa cells

  • Concentrations

    1 μM

  • Incubation Time

    10 min, 2 h

  • Method

    The active RAB5A in cells treated with vacuoin-1 or transfected with RAB5A-CA or RAB5A-DN are examined by a GST-tagged RABEP1 affinity isolation assay.
Animal Study:

[3]
  • Animal Models

    Male Wistar rats

  • Dosages

    40 nM

  • Administration

    intrastriatal infusion

Selleck's MPP+ iodide has been cited by 2 publications

Myeloid-specific blockade of notch signaling alleviates dopaminergic neurodegeneration in Parkinson's disease by dominantly regulating resident microglia activation through NF-κB signaling [ Front Immunol, 2023, 14:1193081] PubMed: 37680624
Myeloid-specific blockade of notch signaling alleviates dopaminergic neurodegeneration in Parkinson's disease by dominantly regulating resident microglia activation through NF-κB signaling [ Front Immunol, 2023, 14:1193081] PubMed: 37680624

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.